Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 9953 - 9960 of 11616 results
Proposed Counterfeit Parts Rule Would Expand Coverage to Commercial Products Sold to Any Federal Agency
June 13, 2014| Blog| Viewpoint
Equity Begets Flexibility: Valuing a Secured Creditor’s Claim in Bankruptcy and Allocating Post-Petition Interest
June 13, 2014| Advisory| Viewpoint
Proposed Counterfeit Parts Rule Would Expand Coverage to Commercial Products Sold to Any Federal Agency
June 13, 2014| Alert| Viewpoint
SEC Commissioner Aguilar Speaks on Cybersecurity Issues for the Boardroom
June 13, 2014| Blog| Viewpoint
The ONC’s Health IT Vision Plan: A Building Under Construction
June 13, 2014| Blog| Viewpoint
Calling All Boards of Directors: Four Recommendations from the SEC
June 13, 2014| Blog| Viewpoint
U.S. Supreme Court Allows Pom Wonderful to Pursue Lanham Act Claims against Coca-Cola
June 12, 2014| Blog| Viewpoint
No Quorum at Senate Nominations Hearing for CPSC's Adler; Three CPSC Nominees Now Waiting for Committee Action
June 12, 2014| Blog| Viewpoint
News & Press Releases
Mintz Announces New Members
December 20, 2024
Mintz announces the election of eight attorneys to Members, effective January 1, 2025. The newly promoted Members join the ranks of the firm’s growing membership, including six new lateral Members who joined the firm in 2024.
Mintz represented the US Department of Energy (DoE) Loan Programs Office (LPO) in the closing of a $1.45 billion loan guarantee to Hanwha Q Cells Georgia, Inc. (QCells), a leading North American crystalline silicon solar manufacturer.
Dealmaking Dormant No More
December 17, 2024
International Chair of Life Sciences Cheryl Reicin recently participated in a Q&A with Pharmaceutical Executive in which she discusses the ongoing effects of the pandemic on dealmaking trends in the pharmaceutical industry. Cheryl specifically mentions how M&A activity began to rise again in 2024 after slowing in 2023, and that she expects acquisitions to continue picking up in 2025.